Antibody Shows Positive Results in Hep C Trial


REHOVOT, Israel-Officials from XTL Biopharmaceuticals are reporting positive results of the first monoclonal antibody to treat hepatitis C (HCV).

XTL-002, the company's monoclonal antibody, has been tested in Phase 1a studies and has reportedly reduced HCV and RNA levels in more than half the patients treated with one dose.

There were no serious adverse effects reported of the intravenous infusions. XTL-002 is a human high-affinity monoclonal antibody.

Hepatitis C is a viral bloodborne disease that attacks the liver and can cause jaundice, fatigue, pain, and vomiting. It can lead to liver damage and cancer. There are an estimated 4 million Americans who have the virus.

XLT Biopharmaceuticals is working on a group of therapies designed to fight a variety of chronic viral infections, drug-resistant bacteria, and systemic fungal infections.

Related Videos
Medical investigators going over data. (AdobeStock 589197902 by Wasan)
CDC logo is seen on a laptop. (Adobe Stock 428450603 by monticellllo)
Association for the Health Care Environment (Logo used with permission)
Ambassador Deborah Birx, , speaks with Infection Control Today about masks in schools and the newest variant.
mRNA technology  (Adobe Stock 485886181 by kaptn)
Ambassador Deborah Birx, MD
Woman lying in hospital bed (Adobe Stock, unknown)
Photo of a model operating room. (Photo courtesy of Indigo-Clean and Kenall Manufacturing)
GIANTmicrobes at the 2023 APIC Annual Conference and Exhibition.  (Photo by the author)
Related Content